LUPIN Stock Analysis

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:3em;padding-top: 38px;;'>LUP</div>
LUPIN -- India Stock  

INR 865.40  5.10  0.59%

Is it time to welcome LUPIN? LUPIN Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The modest gains experienced by current holders of LUPIN LTD may encourage investors to take a closer look at the firm as it closed today at a share price of 862.0 on 3,517,313 in trading volume. The company executives have been quite successful with maneuvering the stock at opportune times to take advantage of all market conditions in June. The stock standard deviation of daily returns for 30 days investing horizon is currently 1.96. The below-average Stock volatility is a good sign for a longer term investment options and for buy-and-hold investors. Additionally, see Stocks Correlation.

Search Stock Analysis

 
Refresh
The LUPIN Stock analysis interface makes it easy to digest most current publicly released information about LUPIN as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. LUPIN stock analysis module also helps to analyze LUPIN price relationship with some important fundamental indicators such as market cap and management efficiency.

LUPIN Stock Analysis Notes

About 49.0% of the company outstanding shares are owned by corporate insiders. The book value of LUPIN was now reported as 277.04. The company recorded loss per share of 5.95. LUPIN LTD last dividend was issued on the 29th of July 2019. The entity had 5:1 split on 27th of August 2010. Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients worldwide. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. LUPIN operates under Drug ManufacturersSpecialty Generic classification in India and is traded on National Stock Exchange of India. To find out more about LUPIN LIMITED contact the company at 91 22 6640 2222 or learn more at http://www.lupin.com.

LUPIN LTD Investment Alerts

The company reported revenue of 153.75 B. Net Loss for the year was (3.99 B) with profit before overhead, payroll, taxes, and interest of 99.44 B.
About 49.0% of the company outstanding shares are owned by corporate insiders

LUPIN Thematic Classifications

Investor Favorites IdeaInvestor Favorites
Equities most commonly found in portfolios of money managers
Healthcare IdeaHealthcare
USA Equities from Healthcare industry as classified by Fama & French

Market Capitalization

The company currently falls under 'Mega-Cap' category with current market capitalization of 419.99 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate LUPIN's market, we take the total number of its shares issued and multiply it by LUPIN's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Profitablity

The company has Profit Margin (PM) of (1.75) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 9.01 % which suggests for every 100 dollars of sales it generated a net operating income of 0.09.

Management Efficiency

The entity has return on total asset (ROA) of 3.27 % which means that it generated profit of $3.27 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of (3.03) %, meaning that it generated substantial loss on money invested by shareholders. LUPIN management efficiency ratios could be used to measure of how well lupin ltd is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.

Technical Drivers

As of the 11th of July 2020, LUPIN secures the risk adjusted performance of 0.2836, and mean deviation of 2.19. Concerning fundamental indicators, the technical analysis model lets you check available technical drivers of LUPIN LTD, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for LUPIN, which can be compared to its peers in the industry. Please verify LUPIN LTD variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if LUPIN LTD is priced favorably, providing market reflects its recent price of 865.4 per share.

LUPIN LTD Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

LUPIN Technical and Predictive Indicators

LUPIN Forecast Models

About LUPIN Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how LUPIN stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling LUPIN shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as LUPIN. By using and applying LUPIN Stock analysis, traders can create a robust methodology for identifying LUPIN entry and exit points for their positions.
Lupin Limited, a pharmaceutical company, develops, produces, and markets a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients worldwide. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India. LUPIN operates under Drug ManufacturersSpecialty Generic classification in India and is traded on National Stock Exchange of India.

Did you try this?

Run Premium Stories Now

   

Premium Stories

Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
All  Next Launch Module
Additionally, see Stocks Correlation. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page